Overview
- Both mainboard IPOs opened on December 8 and close on December 10, with tentative listing on December 15 and allotment expected on December 11.
- Corona Remedies’ Rs 655.37 crore offer is a 100% offer‑for‑sale priced at Rs 1,008–1,062 per share, and day‑one bids reached about 62% by late trade with retail and NII segments leading while QIBs were yet to participate.
- Wakefit Innovations’ Rs 1,288.89 crore issue comprises a Rs 377.18 crore fresh sale plus Rs 911.71 crore OFS at Rs 185–195 per share, and the book was about 0.10 times covered around midday on day one.
- Grey‑market indications reported a roughly Rs 290 premium for Corona Remedies (about 27% over the top band) versus roughly Rs 16 for Wakefit (single‑digit implied gains), noting these unofficial signals can diverge from listing outcomes.
- Anchors committed about Rs 195 crore to Corona Remedies and roughly Rs 580 crore to Wakefit, while most brokerages recommended subscribing to Corona and issued mixed to avoid/neutral calls on Wakefit on valuation and profitability.